ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Bial - Portela C S.A. clinical trials

Part of BIAL Holding, S.A., which holds 100% as of 2022-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 139 studies whose lead sponsor is Bial - Portela C S.A. or the company grouped under it. 1 is recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 6, 2026.

Our grouping of 2 registry names, not the registry’s. See them and correct one ↓

Compare Bial - Portela C with Merck and Insmed →

Pipeline: 2 programs

Each counted once: 2 with a study Bial - Portela C S.A. leads registered in the last two years.

  • Phase 1
  • Phase 2

The 2 programs — sign in to see the list, free: with every program, filter by condition or phase and sort by first study or primary completion.

Not counted: 1 approved drug Bial - Portela C S.A. gives alongside its own in its studies — furosemide (with zamicastat). Our rule: a drug many companies test, in every study Bial - Portela C S.A. led of it in the last two years beside a drug of its own.

“Registry” is the highest phase of Bial - Portela C S.A.’s own registered studies; Bial - Portela C S.A.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Bial - Portela C S.A.’s studies test, most studies first; none is open now — 21 drugs with a page of their own. Each count opens the studies in search.

Studies, none open

Show 11 more

All 139 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now11%
  • Under way, not recruiting11%
  • Completed13194%
  • Stopped early54%
  • Status unknown or other11%

Phase

  • Phase 198
  • Phase 219
  • Phase 313
  • Phase 44

Where

  • Portugal45
  • United Kingdom21
  • France19
  • Germany19
  • Italy10
  • Canada8

Over the years

  1. 1407
  2. 08
  3. 09
  4. 10
  5. 11
  6. 12
  7. 13
  8. 14
  9. 15
  10. 16
  11. 17
  12. 18
  13. 19
  14. 20
  15. 21
  16. 22
  17. 23
  18. 24
  19. 25
  20. 026

By the year each study started; 43 started before 2007. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Bial - Portela C S.A.

  • Bial - Portela C S.A.
    Same company
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    136 studies
  • Bial R&D Investments, S.A.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →

Focus areas

Conditions Bial - Portela C S.A. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 139. Browse all 139 →